• Customer Login
  • Search
KindredBio
  • About
    • Background
    • KindredBio Leadership
    • Board of Directors
  • Products
    • Mirataz® (mirtazapine transdermal ointment)
      • Mirataz home
      • About Feline Weight Loss
      • Mechanism of Action
      • Efficacy
      • Safety
      • Dosing and Administration
      • Resources
      • Mirataz News
      • For Cat Owners
      • Frequently Asked Questions
  • Technology
    • Veterinary Recombinant Biologics
    • Manufacturing Process
  • Pipeline
  • Education
    • KINections
  • Investors
    • Investor Overview
    • Press Releases
    • Events & Presentations
    • Pipeline
      • epoCat™ (feline recombinant erythropoietin)
      • Zimeta™ (dipyrone)
    • Corporate Governance
    • Stock Information
    • Financial Information
    • Investor Resources
  • News
    • Press Releases
  • Contact Us
    • Contact Us
    • Careers
  • Menu

login

You are here: Home / login
Username
Password

» Lost your Password?

News

  • Kindred Biosciences to Participate in Stifel Healthcare Conference and Jefferies London Healthcare ConferenceNovember 14, 2019 - 4:08 pm
  • Kindred Biosciences Announces Third Quarter 2019 Financial ResultsNovember 12, 2019 - 4:04 pm
  • Kindred Biosciences to Announce Third Quarter 2019 Financial ResultsOctober 28, 2019 - 8:36 am

Events

  • Event: Kindred Biosciences to Present at Stifel Healthcare ConferenceNovember 14, 2019 - 4:11 pm
  • Event: Kindred Biosciences to Participate at Jefferies London Healthcare ConferenceNovember 14, 2019 - 4:11 pm
  • Event: Kindred Biosciences to Announce Third Quarter 2019 Financial ResultsOctober 28, 2019 - 8:35 am
$7.77 Stock is No Change 0.00 (0.00%)
KIN (Common Stock)
Previous Close Volume
$7.77 0
Intraday High Intraday Low
$7.93 $7.64
52 Week High 52 Week Low
$13.96 $5.96
Exchange: NASDAQ CM

KindredBio proudly supports
Rabies Free Africa

© Copyright 2012-2019 | Kindred Biosciences, Inc. | 1555 Bayshore Hwy. Suite 200 Burlingame, CA 94010 | Privacy Policy| Website Terms of Use| Forward Looking Statements
Scroll to top